Literature DB >> 27141371

Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.

Danila Valmori1, Maha Ayyoub2.   

Abstract

A strategic challenge facing clinicians treating patients afflicted with non-small cell lung cancer (NSCLC) is the development of approaches that combine conventional and novel therapies, including targeted therapies and immunotherapeutics. In a recent study, we explored the correlation between the expression of the tumor antigen family MAGE-A and the presence of EGFR and KRAS gene mutations in a large cohort of resected NSCLC patient specimens.

Entities:  

Keywords:  MAGE-A; EGFR; KRAS; NSCLC; immune therapy; targeted therapy

Year:  2014        PMID： 27141371      PMCID： PMC4839361          DOI： 10.4161/21624011.2014.947175

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

2.  Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.

Authors:  Maha Ayyoub; Lorenzo Memeo; Emilio Alvarez-Fernández; Cristina Colarossi; Rosario Costanzo; Eleonora Aiello; Daniela Martinetti; Danila Valmori
Journal:  Cancer Immunol Res       Date:  2014-05-27       Impact factor: 11.151

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  XAGE-1 expression in non-small cell lung cancer and antibody response in patients.

Authors:  Kazuhiko Nakagawa; Yuji Noguchi; Akiko Uenaka; Shuichiro Sato; Hideo Okumura; Motoyuki Tanaka; Michihide Shimono; Ali Mohamed Ali Eldib; Toshiro Ono; Nobuya Ohara; Tadashi Yoshino; Kazuki Yamashita; Tsukasa Tsunoda; Motoi Aoe; Nobuyoshi Shimizu; Eiichi Nakayama
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

Review 6.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.

Authors:  Matthew J Scanlan; Ali O Gure; Achim A Jungbluth; Lloyd J Old; Yao-Tseng Chen
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

Review 7.  Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.

Authors:  Kazuhiro Kakimi; Jun Nakajima; Hiromi Wada
Journal:  Lung Cancer       Date:  2008-12-04       Impact factor: 5.705

Review 8.  Immunotherapy in the treatment of non-small cell lung cancer.

Authors:  Raghav Sundar; Richie Soong; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Lung Cancer       Date:  2014-05-14       Impact factor: 5.705

9.  Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

Authors:  Ahmed Hamaï; Karine Duperrier-Amouriaux; Pascale Pignon; Isabelle Raimbaud; Lorenzo Memeo; Cristina Colarossi; Vincenzo Canzonieri; Tiziana Perin; Jean-Marc Classe; Mario Campone; Pascal Jézéquel; Loïc Campion; Maha Ayyoub; Danila Valmori
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962
  10 in total
  1 in total

Review 1.  Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.

Authors:  Roberta Mazzone; Clemens Zwergel; Antonello Mai; Sergio Valente
Journal:  Clin Epigenetics       Date:  2017-05-30       Impact factor: 6.551
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.